Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Axitinib plus immune checkpoint inhibitor: evidence- and expert-based consensus recommendation for treatment optimisation and management of related adverse events
Viktor Grünwald, Martin H. Voss, Brian I. Rini, et al.
British Journal of Cancer (2020) Vol. 123, Iss. 6, pp. 898-904
Open Access | Times Cited: 44

Showing 1-25 of 44 citing articles:

Small Molecule Kinase Inhibitor Drugs (1995–2021): Medical Indication, Pharmacology, and Synthesis
Cecilia C. Ayala-Aguilera, Teresa Valero, Álvaro Lorente‐Macías, et al.
Journal of Medicinal Chemistry (2021) Vol. 65, Iss. 2, pp. 1047-1131
Open Access | Times Cited: 191
First-line immune checkpoint inhibitor-based combinations in unresectable hepatocellular carcinoma: current management and future challenges
Alessandro Rizzo, Angela Dalia Ricci, Gennaro Gadaleta‐Caldarola, et al.
Expert Review of Gastroenterology & Hepatology (2021) Vol. 15, Iss. 11, pp. 1245-1251
Closed Access | Times Cited: 81
Prospective Cardiovascular Surveillance of Immune Checkpoint Inhibitor–Based Combination Therapy in Patients With Advanced Renal Cell Cancer: Data From the Phase III JAVELIN Renal 101 Trial
Brian I. Rini, Javid J. Moslehi, Marc P. Bonaca, et al.
Journal of Clinical Oncology (2022) Vol. 40, Iss. 17, pp. 1929-1938
Open Access | Times Cited: 59
Current Prospects for Treatment of Solid Tumors via Photodynamic, Photothermal, or Ionizing Radiation Therapies Combined with Immune Checkpoint Inhibition (A Review)
Sanjay Anand, Timothy A. Chan, Tayyaba Hasan, et al.
Pharmaceuticals (2021) Vol. 14, Iss. 5, pp. 447-447
Open Access | Times Cited: 45
Construction of a novel choline metabolism-related signature to predict prognosis, immune landscape, and chemotherapy response in colon adenocarcinoma
Cong Liu, Dingwei Liu, Fangfei Wang, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 19
Systematic surveillance of immune-related adverse events in clinical practice and impact of subsequent steroid medication on survival outcomes
Ryosuke Matsukane, Kimitaka Suetsugu, Kojiro Hata, et al.
International Journal of Clinical Oncology (2023) Vol. 28, Iss. 7, pp. 860-871
Closed Access | Times Cited: 11
Histologic findings of liver injury during pembrolizumab-axitinib treatment: a case report
Rita Carrilho Pichel, Hugo Miranda, Diogo Carvalho Sá, et al.
Revista Española de Enfermedades Digestivas (2025)
Open Access
Combination of Anti-Angiogenics and Checkpoint Inhibitors for Renal Cell Carcinoma: Is the Whole Greater Than the Sum of Its Parts?
Eric Jonasch, Michael B. Atkins, Simon Chowdhury, et al.
Cancers (2022) Vol. 14, Iss. 3, pp. 644-644
Open Access | Times Cited: 18
How to deal with renal toxicities from immune-based combination treatments in metastatic renal cell carcinoma. A nephrological consultation for Oncologists
Marcello Tucci, Laura Cosmai, Marta Pirovano, et al.
Cancer Treatment Reviews (2024) Vol. 125, pp. 102692-102692
Closed Access | Times Cited: 3
Combinations of Anti-Angiogenic Agents and Immune Checkpoint Inhibitors in Renal Cell Carcinoma: Best Option?
Estelle Granet-Vaissiere, Félix Lefort, Charlotte Domblides, et al.
Cancers (2023) Vol. 15, Iss. 4, pp. 1048-1048
Open Access | Times Cited: 8
Time to Resolution of Axitinib-Related Adverse Events After Treatment Interruption in Patients With Advanced Renal Cell Carcinoma
Brian I. Rini, Michael B. Atkins, Toni K. Choueiri, et al.
Clinical Genitourinary Cancer (2021) Vol. 19, Iss. 5, pp. e306-e312
Open Access | Times Cited: 14
Adverse events of systemic immune-based combination therapies in the first-line treatment of patients with metastatic renal cell carcinoma: systematic review and network meta-analysis
Fahad Quhal, Keiichiro Mori, Mesut Remzi, et al.
Current Opinion in Urology (2021) Vol. 31, Iss. 4, pp. 332-339
Closed Access | Times Cited: 14
Adverse Events Associated with Immune Checkpoint Inhibitors: Overview of Systematic Reviews
Salmaan Kanji, Sydney Morin, Kyla Agtarap, et al.
Drugs (2022) Vol. 82, Iss. 7, pp. 793-809
Closed Access | Times Cited: 9
Real-World Therapy Management and Outcomes of First-Line Axitinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma in the United States
Yousef Zakharia, Despina Thomaidou, Benjamin Li, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 9
Adverse Events of Axitinib plus Pembrolizumab Versus Lenvatinib plus Pembrolizumab: A Pharmacovigilance Study in Food and Drug Administration Adverse Event Reporting System
Jun Matsumoto, Naohiro Iwata, Shogo Watari, et al.
European Urology Focus (2022) Vol. 9, Iss. 1, pp. 141-144
Closed Access | Times Cited: 8
The need for kidney biopsy in the management of side effects of target and immunotherapy
Roberta Fenoglio, Martina Cozzi, Giulio Del Vecchio, et al.
Frontiers in Nephrology (2023) Vol. 3
Open Access | Times Cited: 4
The Role of Nurses in the Management of Adverse Events in Patients Receiving First-Line Axitinib Plus Immuno-Oncology Agents for Advanced Renal Cell Carcinoma
Sara Parreira, Kathleen H. Burns, Nancy P. Moldawer, et al.
Seminars in Oncology Nursing (2023) Vol. 40, Iss. 1, pp. 151545-151545
Open Access | Times Cited: 4
Multiorgan failure caused by pembrolizumab and axitinib in a woman affected by metastatic clear cell renal cell carcinoma: A case report and literature review
A. Di Marco, Grazia Artioli, Adolfo Favaretto, et al.
Medicine (2024) Vol. 103, Iss. 13, pp. e37606-e37606
Open Access | Times Cited: 1
FDA-approved small molecule kinase inhibitors for cancer treatment (2001–2015): Medical indication, structural optimization, and binding mode Part I
Ying Wang, Xiang Nan, Yanping Duan, et al.
Bioorganic & Medicinal Chemistry (2024) Vol. 111, pp. 117870-117870
Closed Access | Times Cited: 1
Case Report: Successful treatment of late-onset immune checkpoint inhibitor-associated membranous nephropathy in a patient with advanced renal cell carcinoma
Praveen Ratanasrimetha, Vikas D. Reddy, Jaya Kala, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 7
Absorption of the orally active multikinase inhibitor axitinib as a therapeutic index to guide dose titration in metastatic renal cell carcinoma
Masahide Fukudo, Gaku Tamaki, Makoto Azumi, et al.
Investigational New Drugs (2020) Vol. 39, Iss. 2, pp. 595-604
Closed Access | Times Cited: 9
Takotsubo Syndrome in a Patient with Metastatic Renal Cell Carcinoma Treated with Pembrolizumab Plus Axitinib
Giulia Airò, Michele Maffezzoli, Alessandro Lazzarin, et al.
Immunotherapy (2022) Vol. 14, Iss. 16, pp. 1297-1305
Closed Access | Times Cited: 6
A Profile of Avelumab Plus Axitinib in the Treatment of Renal Cell Carcinoma
Manuela Tiako Meyo, Jeanne Chen, François Goldwasser, et al.
Therapeutics and Clinical Risk Management (2022) Vol. Volume 18, pp. 683-698
Open Access | Times Cited: 5
Beyond the Checkpoint: Severe Axitinib-induced Liver Injury
Yee Hui Yeo, Walid S. Ayoub, Ju Dong Yang, et al.
ACG Case Reports Journal (2023) Vol. 10, Iss. 11, pp. e01177-e01177
Open Access | Times Cited: 2
Rare and Insidious Toxicities from New Combination Therapies in Metastatic Renal Cell Cancer: Lessons Learned from Real-Practice
Arianna Dri, Silvio Ken Garattini, M. Cinausero, et al.
Current Oncology (2022) Vol. 29, Iss. 10, pp. 6776-6786
Open Access | Times Cited: 4
Page 1 - Next Page

Scroll to top